Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose

BACKGROUND: The receptor kinase inhibitor toceranib phosphate (Palladia) was approved for use in dogs in 2009 using a dose of 3.25 mg/kg administered every other day. Preliminary data suggests that lower doses of toeceranib may be associated with a reduced adverse event profile while maintaining suf...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernabe, Luis Feo, Portela, Roberta, Nguyen, Sandra, Kisseberth, William C, Pennell, Michael, Yancey, Mark F, London, Cheryl A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850926/
https://www.ncbi.nlm.nih.gov/pubmed/24079884
http://dx.doi.org/10.1186/1746-6148-9-190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850926/
https://www.ncbi.nlm.nih.gov/pubmed/24079884
http://dx.doi.org/10.1186/1746-6148-9-190

Ejemplares similares